Summary
The concentrations of the 5-S-cysteinyl adducts of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and 3,4-dihydroxyphenylalanine (DOPA) and the levels of noradrenaline (NA), DA, DOPAC and DOPA were determined in the putamen (PUT), caudate nucleus (CN) and substantia nigra (SN) of human post mortem brains with or without depigmentation and degeneration of the SN. The levels of DA, DOPAC and DOPA decreased with the degree of depigmentation and degeneration in the three brain regions while NA levels only decreased in SN and PUT. In general, the concentrations of the 5-S-cysteinyl adducts did not differ, but the ratios of 5-S-cysteinyl-DA/DA, 5-S-cysteinyl-DOPAC/DOPAC and 5-S-cysteinyl-DOPA/DOPA were higher in patients with a more depigmentated and degenerated SN, except for the 5-S-cysteinyl-DA/DA ratio in the PUT. Higher ratios were also found in the cell body areas compared to the neuron terminal areas.
Thus depigmentation and degeneration of dopaminergic SN neurons, seem to be correlated to enhanced rates of autoxidation, possibly due to an impaired antioxidant capacity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agrup G, Falck B, Jacobsson S, Rorsman H, Rosengren AM, Rosengren E (1974) 5-S-Cysteinyldopa in melanomas of caucasians. Acta Derm Venereol (Stockholm) 54: 21–23
Agrup G, Edholm L-E, Rorsman H, Rosengren E (1983) Diastereomers of 5-S-cysteinyl-DOPA. Acta Derm Venereol (Stockholm) 63: 59–61
Ambani LM, Melvin H, van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 32: 114–118
Anton AH, Sayre DF (1962) A study of the factors affecting the aluminium oxidetrihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138: 360–375
Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 19 [Suppl]: 89–103
Dahlqvist I, Falck B, Jacobsson S, Rorsman H, Rosengren AM, Rosengren E (1972) 5-S-Cysteinyldopa in the urine of melanoma patients. Communications from the Department of Anatomy, University of Lund, Sweden, No. 7
Das KC, Abramson MB, Katzman R (1978) Neuronal pigments: spectroscopic characterization of human brain melanin. J Neurochem 30: 601–605
Dexter DT, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Mardsen CD (1986) Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet ii: 639–640
Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Mardsen CD (1987) Increased nigral iron content in post mortem parkinsonian brain. Lancet ii: 1219–1220
Fehling C, Hansson C, Poulsen J, Rorsman H, Rosengren E (1981) 5-S-Cysteinyldopa in ganglion stellatum. J Neural Transm 52: 251–257
Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451–454
Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guineapig striatum following reserpine treatment. J Neural Transm 76: 155–161
Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633–643
Graham DG, Tiffany SM, Bell WRJr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C 1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653
Ito S, Novellino E, Chiocarra F, Misuraca O, Prota G (1980) Co-polymerization of dopa and cysteinyldopa in melanogenesis in vitro. Experientia 36: 822–823
Ito S, Fujita K, Yoshioka M, Sienko D, Nagatsu T (1986) Identification of 5-S- and 2-S-cysteinyldopamine and 5-C-glutathionyldopamine formed from dopamine by highperformance liquid chromatography with electrochemical detection. J Chromatogr 375: 134–140
Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876–880
Milliken GA, Johnson DE (1984) Analyses of messy data. Lifetime Learning Publications, Belmont, California, U.S.A.
Moldéus P, Nordenskjöld M, Bolcsfoldi G, Eiche A, Haglund U, Lambert B (1983) Genetic toxicity of dopamine. Mutat Res 124: 9–24
Nordgren L, Rorsman H, Rosengren A-M, Rosengren E (1971) Dopa and dopamine in the pigment of substantia nigra. Experientia 27: 1178–1179
Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310
Prota G, Rorsman H, Rosengren AM, Rosengren E (1976) Pheaomelanic pigment from a human melanoma. Experientia 32: 970–971
Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathion and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520
Rodgers AD, Curzon G (1975) Melanin formation by human brain in vitro. J Neurochem 24: 1123–1129
Rorsman H, Agrup G, Hansson C, Rosengren AM, Rosengren E (1979) Detection of pheomelanins. In: Klaus SN (ed) Pigment cell, vol 4. Karger, Basel, pp 243–253
Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63: 247–253
Scheulen M, Wollenberg P, Bolt HM, Kappus H, Remmer H (1975) Irreversible binding of dopa and dopamine metabolites to protein by rat liver microsomes. Biochem Biophys Res Commun 66: 1396–1400
Sealy R, Hyde J, Felix C, Menon IA, Prota G (1982) Eumelanins and pheomelanins: characterisation by electron spin resonance. Science 217: 545–547
Vogel CL, Dhru Dh, Rorsman H, Rosengren AM, Rosengren E (1974) Dopa and 5-S-cysteinyldopa in malignant melanoma in Ugandan Africans. Acta Derm Venereol (Stockholm) 54: 19–21
Wick MM (1978) Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Derm 71: 163–164
Wick MM, Byers L, Frei E III (1977) L-Dopa: selective toxicity for melanoma cells in vitro. Science 197: 468–469
Wick MM (1980) Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res 40: 1414–1418
Wiesel F-A, Sedvall G (1974) Post-mortal changes of dopamine and homovanillic acid levels in rat striatum as measured by mass fragmentography. Brain Res 65: 547–550
Van Woert MH, Prasad KN, Borg DC (1967) Spectroscopic studies of substantia nigra pigment in human subjects. J Neurochem 14: 707–716
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fornstedt, B., Brun, A., Rosengren, E. et al. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Gen Sect 1, 279–295 (1989). https://doi.org/10.1007/BF02263482
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02263482